chevron_leftBack
B
As of 24 April 2025, BCAL Diagnostics Ltd. has a market cap of $19.86M USD, ranking #29869 globally and #832 in Australia. It ranks #2990 in the Healthcare sector, and #151 in the Diagnostics & Research industry.
Key Stats
Market Cap
$19.86MUSD
31.11M AUD
Enterprise Value
$16.22MUSD
25.4M AUD
Revenue (TTM)
$1.67MUSD
2.62M AUD
EBITDA (TTM)
-$4.41MUSD
-6.91M AUD
Net Income (TTM)
-$5.1MUSD
-7.99M AUD
EBITDA Margin
-264%
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Diagnostics & Research
CEO
Shane Ryan
open_in_new
Founded
2010
Website
bcaldiagnostics.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -5.6% | -11% | -13% | -6.6% | -29% | -11% |
Upcoming Earnings
Earnings Date
Wed, May 28
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
BDX
BCAL Diagnostics Ltd Ordinary Shares
ISIN: AU0000160921
Shares Out.:
Shares Outstanding:
365.968M1
|
0.0850 AUD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About BCAL Diagnostics Ltd.
BCAL Diagnostics Limited, a screening and diagnostic company, engages in developing a novel blood screening test to improve the diagnosis and monitoring of breast cancer. It develops BREASTEST, a laboratory developed test or in-house in vitro diagnostic blood test. The company was incorporated in 2010 and is headquartered in Sydney, Australia.
